Results 191 to 200 of about 6,598 (226)

Cardiovascular function in people with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A cross-sectional, observational, single-centre study

L J, Anthony I. Shepherd, Jo Corbett, Maria Perissiou, Gary Connett, Julian Legg, Mark I. Allenby, T. Daniels, Don S. Urquhart, Kelly A. Mackintosh, Melitta A. McNarry, Zoe L. Saynor   +11 more
openalex   +1 more source

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor. [PDF]

JHEP Rep
Mouliade C, Parlati L, Tzedakis S, Collier M, Bouam S, Vallet-Pichard A, D'Halluin-Venier V, Kanaan R, Pol S, Sogni P, Burgel PR, Mallet V, Demosthenes Research Group.   +12 more
europepmc   +1 more source

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study. [PDF]

Int J Mol Sci
Volpi S, Ambroni M, Buzzetti R, Cimino G, Gramegna A, Lucanto MC, Ripani P, Ros M, Salvatore D, Spada E, Braggion C, Italian SITTMA Study Group.   +11 more
europepmc   +1 more source

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase-1 in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Sankararaman S, Prunty L, Pamer C, Thavamani A, Roesch E, Schindler T.   +5 more
europepmc   +1 more source

A systematic review and meta-analysis of the treatment modalities available for children afflicted from cystic fibrosis. [PDF]

BMC Pediatr
Alruwaili TAM, Alanazi MF, Alruwaili BF, Fayed HK, Elsaeed M, Alnazi TD, Aljared A, Alanazi AMW, Alanazi AM, Alsharari SD, Alshammari A, Saad K.   +11 more
europepmc   +1 more source

Top 10 drugs 2024-25. [PDF]

Aust Prescr
europepmc   +1 more source